Introducing StaClear® Luer Slip and Norm-Ject® Less Fill

Jul 27, 2023 | Company news

Avastin Bevacizumab 503B | Pine Pharmaceuticals

Pine Pharmaceuticals is pleased to introduce StaClear® Luer Slip and NORM-JECT® Less Fill, our all-new syringe options for repackaged bevacizumab.

Designed to provide exceptional quality, StaClear® Luer Slip and NORM-JECT® Less Fill syringes now offer a low dead space design that reduces drug wastage.

StaClear® Luer Slip

  • FDA-cleared* syringe for intravitreal use
  • 1.25 mg/0.05 mL**
  • Low dead space design reduces drug wastage
  • 31-gauge OcuJect SteriCap® Mini Needle provided

NORM-JECT® Less Fill

  • Silicone-free syringe
  • 1.25 mg/0.05 mL**
  • Low dead space design reduces drug wastage
  • Separate needle required


Guided by integrity, every product that leaves our FDA-registered outsourcing facility is prepared through a strictly controlled process, ensuring top-drug quality for your patients.

That is why, with StaClear® Luer Slip and NORM-JECT® Less Fill, health systems can be confident they are providing cost-effective solutions that deliver exceptional patient care.

Contact our Sales team to learn more and pre-order today.



*Bevacizumab is not FDA-approved for intravitreal use. StaClear® is the first fillable syringe FDA-cleared for intravitreal use. StaClear® is a registered trademark of TriboFilm Research. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

**Overfilled to allow final administration dosage.

©2023 Pine Pharmaceuticals. All rights reserved.